financetom
Business
financetom
/
Business
/
What's Going On With Ulta Beauty Stock Friday?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
What's Going On With Ulta Beauty Stock Friday?
May 31, 2024 11:58 AM

Ulta Beauty, Inc. ( ULTA ) shares are volatile Friday following better-than-expected earnings results for the first quarter. Here’s a look at what’s going on.

What To Know: Ulta reported financial earnings for the first quarter of fiscal-year 2024 after the market close on Thursday.

The company reported EPS of $6.47 which came in ahead of analyst estimates of $6.22. In addition, Ulta announced revenue of $2.726 billion beating analyst estimates of $2.721 billion.

The company updated their guidance for the fiscal-year 2024. Ulta sees EPS between $25.2 and $26 and net sales from $11.5 billion to $11.6 billion. Originally, Ulta expected EPS from $26.2 to $27 and net sales between 11.7 billion and 11.8 billion.

Analyst Changes: Following the earnings report, several analyst released price target adjustments.

Evercore ISI Group analyst Michael Binetti maintains Ulta Beauty ( ULTA ) with a Outperform and lowers the price target from $630 to $500.

Telsey Advisory Group analyst Dana Telsey maintains Ulta Beauty ( ULTA ) with a Outperform and maintains $500 price target.

Piper Sandler analyst Korinne Wolfmeyer maintains Ulta Beauty ( ULTA ) with an Overweight and lowers the price target from $505 to $498.

BMO Capital analyst Simeon Siegel maintains Ulta Beauty ( ULTA ) with a Market Perform and lowers the price target from $540 to $500.

Related Link: The Analyst Landscape: 18 Takes On Dollar Tree

ULTA Price Action: Ulta shares are currently higher 1.15% and trading at $390 per data from Benzinga Pro.

Image: Photo via Wikimedia Commons

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-Merck To Acquire Investigational B-Cell Depletion Therapy, CN201, From Curon Biopharmaceutical
BRIEF-Merck To Acquire Investigational B-Cell Depletion Therapy, CN201, From Curon Biopharmaceutical
Aug 9, 2024
Aug 9 (Reuters) - Merck & Co Inc ( MRK ): * MERCK TO ACQUIRE INVESTIGATIONAL B-CELL DEPLETION THERAPY, CN201, FROM CURON BIOPHARMACEUTICAL * MERCK & CO INC ( MRK ) - PAYS $700M UPFRONT FOR CN201 * MERCK & CO INC ( MRK ) - CURON ELIGIBLE FOR $600M MILESTONE PAYMENTS * MERCK & CO INC ( MRK )...
BBVA Comments on Thursday's Rate Cuts at Mexico, Peru Central Banks
BBVA Comments on Thursday's Rate Cuts at Mexico, Peru Central Banks
Aug 9, 2024
07:12 AM EDT, 08/09/2024 (MT Newswires) -- The Board of Peru's central bank (BCRP) decided to cut the policy rate by 25 basis points to 5.50% on Thursday, noted BBVA Research. The BCRP expects inflation to remain close to the center of the target range (2% +/- 1%) in the following months and core inflation to follow a downward trend....
Quarterhill Q2 Net Loss Narrows as Revenue Rises
Quarterhill Q2 Net Loss Narrows as Revenue Rises
Aug 9, 2024
07:10 AM EDT, 08/09/2024 (MT Newswires) -- Quarterhill ( QTRHF ) , a provider of tolling and enforcement solutions in the Intelligent Transportation System industry, on Friday said its second-quarter net loss narrowed as revenue increased 7.5%. The net loss came in at US$3 million, or US$0.03 per diluted share, narrowing from a loss of US$21.8 million, or US$0.19 per...
Market Chatter: Intel's Senior Unsecured Rating Downgraded by Moody's
Market Chatter: Intel's Senior Unsecured Rating Downgraded by Moody's
Aug 9, 2024
07:05 AM EDT, 08/09/2024 (MT Newswires) -- Intel ( INTC ) 's senior unsecured rating was downgraded by Moody's to BAA1 from A3 rating over apprehensions about the chipmaker's profitability, Reuters reported Thursday citing the credit ratings firm. Moody's also changed Intel's ( INTC ) unsecured ratings outlook to negative from stable, while affirming the company's Prime-2 short-term commercial paper...
Copyright 2023-2026 - www.financetom.com All Rights Reserved